Table 1.
Patient characteristics.
| IGF‐1R low (n = 830) | IGF‐1R high (n = 1,616) | p‐Value | |
|---|---|---|---|
| n (%) | n (%) | ||
| Age | |||
| <55 | 110 (13.3) | 221 (13.7) | 0.33 |
| 55–59 | 175 (21.1) | 321 (19.9) | |
| 60–64 | 145 (17.5) | 315 (19.5) | |
| 65–69 | 123 (14.8) | 277 (17.1) | |
| 70–74 | 130 (15.7) | 222 (13.7) | |
| ≥75 | 147 (17.7) | 260 (16.1) | |
| BMI | |||
| <20 | 23 (2.8) | 39 (2.4) | 0.81 |
| 20–24 | 253 (30.5) | 484 (30) | |
| 25–29 | 282 (34) | 559 (34.6) | |
| ≥30 | 176 (21.2) | 366 (22.6) | |
| Unknown | 96 (11.6) | 168 (10.4) | |
| T‐stage | |||
| T1 | 359 (43.3) | 733 (45.4) | 0.62 |
| T2 | 411 (49.5) | 781 (48.3) | |
| T3 | 35 (4.2) | 62 (3.8) | |
| T4 | 22 (2.7) | 38 (2.4) | |
| Missing | 3 (0.4) | 2 (0.1) | |
| N‐stage | |||
| N0 | 239 (28.8) | 517 (32) | 0.16 |
| N+ | 591 (71.2) | 1097 (67.9) | |
| Unknown | 0 (0) | 2 (0.1) | |
| Histological grade | |||
| Grade 1 | 130 (15.7) | 227 (14) | 0.06 |
| Grade 2 | 368 (44.3) | 717 (44.4) | |
| Grade 3 | 270 (32.5) | 586 (36.3) | |
| Unknown | 62 (7.5) | 86 (5.3) | |
| ER‐ and/or PR‐status | |||
| Negative | 3 (0.4) | 3 (0.2) | 0.33 |
| Positive | 827 (99.6) | 1613 (99.8) | |
| Most extensive surgery | |||
| No surgery | 0 (0) | 1 (0.1) | 0.77 |
| BCS | 380 (45.8) | 735 (45.5) | |
| Mastectomy | 450 (54.2) | 880 (54.5) | |
| Radiotherapy | |||
| No | 318 (38.3) | 623 (38.6) | 0.92 |
| Yes | 511 (61.6) | 990 (61.3) | |
| Unknown | 1 (0.1) | 3 (0.2) | |
| Chemotherapy | |||
| No | 592 (71.3) | 1119 (69.2) | 0.29 |
| Yes | 238 (28.7) | 497 (30.8) | |
| Randomisation | |||
| TAM → EXE | 402 (48.4) | 822 (50.9) | 0.26 |
| EXE | 428 (51.6) | 794 (49.1) | |
| Metformin user | |||
| No | 780 (94) | 1511 (93.5) | 0.65 |
| Yes | 50 (6) | 105 (6.5) | |